David Taylor and Emma Walmsley are two prominent corporate leaders best known for running Procter & Gamble and GSK, respectively. Public company records do not show a formal business partnership, shared corporate board, family relationship, or direct employment connection between them, but their careers overlap significantly as leaders of large global consumer-facing companies.
In this context, “David Taylor” most plausibly refers to David S. Taylor, the former chairman, president and CEO of Procter & Gamble. He led P&G while Dame Emma Walmsley was leading GSK, giving the pair several years of overlapping CEO tenure and similar experience in consumer brands, global operations and large-scale corporate transformation.
What Does “david taylor and emma walmsley” Refer To?
There is no well-documented corporate deal or personal relationship specifically linking David S. Taylor and Emma Walmsley. Their strongest identifiable connection is professional similarity rather than a formal partnership.
Taylor served as P&G’s president and CEO from November 2015 until November 2021, after which he became executive chairman. Walmsley became GSK’s CEO in April 2017 and remained in the role until the end of December 2025. Their periods as active CEOs therefore overlapped from April 2017 until November 2021.
Both also came to their top jobs with substantial experience in businesses closely connected to everyday consumers. Taylor had managed P&G businesses including beauty, grooming, health care, home care and family care. Walmsley had previously led GSK Consumer Healthcare after spending 17 years at L’Oréal.
| Detail | David S. Taylor | Dame Emma Walmsley |
|---|---|---|
| Best known for | Former CEO and chairman of Procter & Gamble | Former CEO of GSK |
| CEO tenure | November 2015 to November 2021 | April 2017 to December 2025 |
| Earlier experience | Manufacturing, operations, brand management and consumer products | Marketing, consumer products and global management |
| Major company associated with | Procter & Gamble | GSK |
| Important later board role | Delta Air Lines | Microsoft |
| Major transformation associated with tenure | P&G portfolio and organizational transformation | GSK R&D restructuring and separation of Haleon |
Who Is David S. Taylor?
David S. Taylor spent more than four decades at Procter & Gamble. He joined the company in 1980 and gradually moved through manufacturing, supply operations and senior business leadership before taking responsibility for businesses including Family Care, Home Care, Health & Grooming, and Beauty, Grooming & Health Care.
Taylor studied electrical engineering at Duke University. His early career was rooted more heavily in engineering and factory operations than traditional corporate finance, but he later moved into brand management and global consumer businesses. Delta’s official biography has also highlighted his experience across North America, Europe and Asia.
Taylor’s Rise to P&G CEO
P&G announced Taylor’s appointment as president and CEO in July 2015, with the change becoming effective on November 1 of that year. He succeeded A.G. Lafley at a time when the company was already simplifying its portfolio and focusing resources on a smaller collection of major categories and brands.
Taylor subsequently became chairman as well. During his leadership period, P&G continued restructuring its organization and increasingly emphasized category-level accountability, product superiority, productivity and balanced sales and profit growth.
The company’s fiscal 2021 results illustrate its position near the end of Taylor’s CEO tenure. P&G reported a 7% increase in net sales, 6% organic sales growth and an 11% increase in diluted net earnings per share for the year. These are company-reported results and should not be attributed to a single executive alone, but they provide useful context for the condition of P&G when the CEO transition occurred.
Why Did David Taylor Leave P&G?
P&G announced in July 2021 that Jon Moeller would replace Taylor as president and CEO on November 1, 2021. Taylor then became executive chairman, advising the new leadership and continuing to lead the board.
His retirement from P&G became effective in 2022, when Moeller also took over as chairman. P&G credited Taylor with completing portfolio restructuring and significant organizational changes during his leadership period.
What Is David Taylor Doing Now?
Taylor moved into board and advisory work after P&G. Delta Air Lines has identified him as its non-executive chair of the board, including in company announcements concerning board appointments.
He also became a Duke University trustee in July 2023. In 2022, private investment firm Clayton, Dubilier & Rice appointed him a senior operating advisor to CD&R-managed funds, drawing on his experience in manufacturing, supply chains, marketing and global business.
Who Is Dame Emma Walmsley?
Dame Emma Walmsley built much of her early career in consumer products rather than pharmaceuticals. Before GSK, she spent 17 years at L’Oréal in positions covering marketing and general management in markets including the UK, Europe, the United States and China.
She joined GSK in 2010 as President of Consumer Healthcare Europe and President Designate of Worldwide Consumer Healthcare. She later became president and then CEO of the consumer health operation, including leadership of the business created through GSK’s major transaction with Novartis.
Walmsley was named GSK CEO-designate in September 2016 and formally became chief executive on April 1, 2017. She was the first woman to lead GSK and became one of the most prominent female executives in the global pharmaceutical industry.
How Emma Walmsley Changed GSK
One of Walmsley’s early priorities was rebuilding GSK’s pharmaceutical research pipeline. In 2018, GSK outlined a revised R&D strategy centered particularly on immunology, human genetics and new technologies, while reallocating resources toward research and new-product development.
Another defining change was the restructuring of GSK’s consumer health operations. GSK combined its consumer health business with Pfizer’s consumer healthcare portfolio in 2019, with GSK controlling 68% of the resulting joint venture and Pfizer holding 32%. Walmsley chaired that venture.
The business was subsequently separated from GSK and listed independently as Haleon in July 2022. Its portfolio included brands such as Sensodyne, Panadol, Advil, Voltaren and Centrum. The separation left GSK more concentrated on vaccines and prescription medicines.
By 2024, GSK reported £31.4 billion in annual sales, with specialty medicines growing 19% at constant exchange rates and oncology sales nearly doubling. Again, these results reflect the work of an entire organization rather than one executive, but they show how GSK’s business mix had shifted during Walmsley’s tenure.
Why Did Emma Walmsley Leave GSK?
GSK announced in September 2025 that Luke Miels would succeed Walmsley. Miels assumed full CEO responsibilities and joined the board on January 1, 2026.
Walmsley stepped down as GSK CEO and director on December 31, 2025. GSK’s formal departure arrangements kept her employed until September 30, 2026 to assist with the transition and advise on matters including geopolitics and emerging technologies.
That means, as of October 1, 2026, the transition period disclosed by GSK has ended.
Walmsley remains associated with Microsoft. She joined Microsoft’s board as an independent director in December 2019, and Microsoft shareholder records show she was re-elected in December 2025. Microsoft’s 2026 leadership information identifies her as the former CEO and director of GSK.
David Taylor and Emma Walmsley: What They Have in Common
The similarities between Taylor and Walmsley are substantial enough to explain why their names may appear together in searches, even without a direct relationship.
Both Came From Consumer-Focused Businesses
Taylor spent decades building and managing products sold directly to households, including Pampers, Gillette, Pantene, Head & Shoulders and other P&G categories.
Walmsley spent 17 years at L’Oréal and then led GSK Consumer Healthcare before becoming CEO of the wider pharmaceutical company. Her earlier career therefore involved brands, marketing and consumer behavior more heavily than laboratory science.
Both Led Major Corporate Transformations
Taylor’s P&G tenure included restructuring the company’s organization after a major portfolio simplification. P&G later credited him with helping restore consistent balanced growth and making important organizational changes.
Walmsley’s transformation was structurally different. GSK increased its emphasis on pharmaceutical R&D, built up specialty medicines and vaccines, and separated Consumer Healthcare as Haleon.
Both Led Through the COVID-19 Period
Taylor was still CEO of P&G throughout the most disruptive stages of the COVID-19 pandemic in 2020 and most of 2021. P&G had to manage elevated demand for household products, manufacturing continuity and global supply-chain disruption.
Walmsley simultaneously led GSK, where the pandemic created a very different set of challenges involving vaccines, medicines, clinical research, manufacturing and public-health expectations.
Their roles were therefore comparable in scale but very different in responsibility.
Also Read: Michael Jackson and Emma Walmsley
Important Differences Between Their Careers
Taylor’s career was unusually concentrated. He joined P&G after university in 1980 and remained with the same company for more than 40 years before retiring. His expertise developed across P&G’s manufacturing, operations, branding and consumer businesses.
Walmsley’s career crossed two large multinational groups. She developed her consumer-marketing background at L’Oréal before moving into healthcare through GSK, eventually overseeing a business centered on pharmaceuticals and vaccines.
Their later board careers also differ. Taylor became non-executive chair at Delta Air Lines and a Duke trustee, while Walmsley has served as an independent Microsoft director.
David Taylor and Emma Walmsley Timeline
| Year | David Taylor | Emma Walmsley |
|---|---|---|
| 2010 | Senior P&G executive | Joined GSK from L’Oréal |
| 2015 | Appointed P&G president and CEO | Became CEO of GSK Consumer Healthcare joint venture |
| 2017 | P&G chairman and CEO | Became GSK CEO on April 1 |
| 2019 | Joined Delta Air Lines board | Joined Microsoft board; chaired GSK-Pfizer Consumer Healthcare JV |
| 2021 | Stepped down as P&G CEO and became executive chairman | Continued leading GSK and preparing Consumer Healthcare separation |
| 2022 | Retired from P&G; joined CD&R as senior operating advisor | Oversaw Haleon’s separation and listing |
| 2023 | Joined Duke University Board of Trustees | Continued as GSK CEO and Microsoft director |
| 2025 | Serving as Delta’s non-executive chair | GSK announced Luke Miels as successor |
| 2026 | Continues post-P&G board and advisory career | GSK CEO tenure already ended; disclosed GSK employment ended September 30 |
Are Their Net Worth Figures Publicly Verified?
Neither P&G nor GSK publishes an independently verified personal net worth for Taylor or Walmsley. Online net-worth estimates should therefore not be treated as established facts.
What can be verified is executive compensation. P&G’s SEC filing reported Taylor’s total fiscal 2021-22 compensation as $18.6 million while he was executive chairman and former CEO, down from about $23.9 million in fiscal 2020-21. Those totals included salary, bonuses, stock awards, option awards and other compensation.
GSK’s 2025 remuneration report recorded £15.681 million in total remuneration for Walmsley for 2025. That figure included performance-related compensation and should not be interpreted as annual salary or personal wealth.
The figures also should not be directly compared without accounting for different currencies, reporting periods and compensation structures.
FAQ
Are David Taylor and Emma Walmsley related?
There is no credible public evidence that David S. Taylor and Emma Walmsley are related. Their connection in search results is best understood through their high-profile business careers.
Did David Taylor and Emma Walmsley ever work together?
Official biographies and corporate records do not show them working for the same company or serving together on the same corporate board. They did, however, lead P&G and GSK simultaneously between 2017 and 2021.
Which David Taylor is connected with Emma Walmsley in business searches?
The most relevant person is David S. Taylor, the former chairman, president and CEO of Procter & Gamble. “David Taylor” is a common name, so searches without a company or middle initial can refer to numerous unrelated people.
Are David Taylor and Emma Walmsley still CEOs?
No. Taylor stopped serving as P&G CEO in November 2021 and retired from the company in 2022. Walmsley stepped down as GSK CEO at the end of December 2025, when Luke Miels succeeded her on January 1, 2026.
What does David Taylor do after P&G?
Taylor has moved into governance and advisory positions. Recent official records identify him as Delta Air Lines’ non-executive board chair, while Duke appointed him to its Board of Trustees in 2023. He was also appointed a senior operating advisor to CD&R-managed funds in 2022.
What does Emma Walmsley do after GSK?
Her formal GSK transition employment ended on September 30, 2026. Microsoft continues to identify Walmsley as one of its directors, following her latest shareholder re-election in December 2025.
Also Read: Richard Branson and Emma Walmsley
